Skip to main content

Advertisement

SpringerLink
Log in

Cancer therapy

Using genetics to predict toxicity of cancer immunotherapy

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Impact of an IL7 variant on patients with cancer.

References

  1. Boutros, C. et al. Nat. Rev. Clin. Oncol. 13, 473–486 (2016).

    Article  CAS  Google Scholar 

  2. Postow, M. A., Sidlow, R. & Hellmann, M. D. N. Engl. J. Med. 378, 158–168 (2018).

    Article  CAS  Google Scholar 

  3. Hua, C. et al. JAMA Dermatol. 152, 45–51 (2016).

    Article  Google Scholar 

  4. Groha, S. Nat. Med. https://doi.org/10.1038/s41591-022-02094-6 (2022).

    Article  Google Scholar 

  5. Taylor, C. A. Nat. Med. https://doi.org/10.1038/s41591-022-02095-5 (2022).

    Article  Google Scholar 

  6. Barata, J. T., Durum, S. K. & Seddon, B. Nat. Immunol. 20, 1584–1593 (2019).

    Article  CAS  Google Scholar 

  7. Dooms, H. J. Autoimmun. 45, 40–48 (2013).

    Article  CAS  Google Scholar 

  8. Rivière, E. et al. Arthritis Rheumatol. 73, 631–640 (2021).

    Article  Google Scholar 

  9. Pachynski, R. K. et al. J. Immunother. Cancer 9, e002903 (2021).

    Article  Google Scholar 

  10. Murakami, S. & Jaffrey, S. R. Mol. Cell 82, 2236–2251 (2022).

    Article  CAS  Google Scholar 

  11. Childs-Disney, J. L. et al. Nat. Rev. Drug Discov. 21, 736–762 (2022).

    Article  CAS  Google Scholar 

  12. Stanley, R. F. & Abdel-Wahab, O. Nat. Cancer 3, 536–546 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncologic Medicine, Gustave Roussy, Villejuif, France

    Caroline Robert

  2. INSERM U981, Gustave Roussy and Université Paris–Saclay, Villejuif, France

    Caroline Robert

  3. Institut Curie, Université Paris–Saclay, PSL Research University, CNRS UMR3348, INSERM U1278, Orsay, France

    Stéphan Vagner

  4. Department of Rheumatology, Université Paris–Saclay, INSERM UMR1184, Hôpital Bicêtre, FHU CARE (Cancer and Autoimmunity Relationships), Assistance Publique–Hôpitaux de Paris, Le Kremlin Bicêtre, France

    Xavier Mariette

Authors
  1. Caroline Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stéphan Vagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xavier Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline Robert.

Ethics declarations

Competing interests

C.R. is an occasional consultant for Roche, BMS, MSD, Sanofi, AstraZeneca, Pierre Fabre, Novartis and scientific co-Founder of Ribonexus; S.V. is scientific co-founder of Ribonexus Xavier Mariette is an occasional consultant for AstraZeneca, Novartis, BMS, Galapagos, Pfizer, GSK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Robert, C., Vagner, S. & Mariette, X. Using genetics to predict toxicity of cancer immunotherapy. Nat Med 28, 2471–2472 (2022). https://doi.org/10.1038/s41591-022-02096-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02096-4

  • Springer Nature America, Inc.

Search

Navigation